Company / SG&A Expense
Barinthus Biotherapeutics plc. SG&A Expense History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$40.8M
FY2025
5-year range
$6.4M / $40.8M
FY2021-FY2025
Trend
+2.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $6M to $41M over the past 2 years.
Based on SEC 10-K filings.
$41M in FY2025 with a 3-year CAGR of +17.6%.
Increased from $6M to $41M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +17.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +17.6%, indicating consistent growth.
- In FY2025, sg&a expense increased 2.5% year-over-year.
- Lowest sg&a expense in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.06 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $40.8M | +2.5% |
| FY2024 | $39.8M | +523.1% |
| FY2023 | $6.4M | -74.5% |
| FY2022 | $25.1M | +139.7% |
| FY2021 | $10.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026